Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Goldenwell Biotech (GWLL) Return on Sales (2021 - 2025)

Goldenwell Biotech filings provide 5 years of Return on Sales readings, the most recent being 1.29% for Q3 2025.

  • On a quarterly basis, Return on Sales rose 184.0% to 1.29% in Q3 2025 year-over-year; TTM through Sep 2025 was 1.29%, a 184.0% increase, with the full-year FY2024 number at 9.46%, down 882.0% from a year prior.
  • Return on Sales hit 1.29% in Q3 2025 for Goldenwell Biotech, down from 0.34% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 20.74% in Q1 2025 to a low of 4.3% in Q4 2024.
  • Median Return on Sales over the past 5 years was 0.57% (2023), compared with a mean of 0.14%.
  • Biggest five-year swings in Return on Sales: tumbled -350bps in 2024 and later soared 2198bps in 2025.
  • Goldenwell Biotech's Return on Sales stood at 0.06% in 2021, then crashed by -242bps to 0.21% in 2022, then tumbled by -288bps to 0.8% in 2023, then plummeted by -438bps to 4.3% in 2024, then soared by 70bps to 1.29% in 2025.
  • The last three reported values for Return on Sales were 1.29% (Q3 2025), 0.34% (Q2 2025), and 20.74% (Q1 2025) per Business Quant data.